Koretsune, Yuji http://orcid.org/0000-0002-0566-4856
Sone, Miyuki
Arai, Yasuaki
Sugawara, Shunsuke
Itou, Chihiro
Kimura, Shintaro
Kusumoto, Masahiko
Funding for this research was provided by:
This study was funded by the National Cancer Center under the National Cancer Center Research and Development Fund. (2020-J-3)
Article History
Received: 9 January 2021
Accepted: 8 April 2021
First Online: 11 May 2021
Declarations
:
: Miyuki Sone has received a research grant from CANON MEDICAL SYSTEMS. Masahiko Kusumoto has received a research grant from CANON MEDICAL SYSTEMS, a speaker honorarium from Ono pharmaceutical Co, Ltd and AstraZeneca K.K., and MSD K.K. Yasuaki Arai has received royalties from Sumitomo Bakelite and speaker honorarium from Merit Medical Systems, Fuji Pharma, Canon Medical Systems, Terumo International systems, Bristol Meyer Squibb, Sumitomo Bakelite, Nippon Kayaku, Boston Scientific Japan, Bayer Pharmaceuticals, Japan Lifeline, Taiho Pharmaceutical, Guerbet Japan, Guerbet Asia Pacific, Kyorin Pharmaceutical, and AstraZeneca plc.
: For this type of study, consent for publication is not required.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study formal, consent is not required. This retrospective study was approved by the Institutional Ethics Committee.
: This study has obtained IRB approval from the Institutional Ethics Committee and the need for informed consent was waived.